Fadrozole


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:10630580IVR0.6 mg/kg/day 0.6 mg/kg/dayAlterations in vaginal openingReproductive endocrine-mediated perturbations
IVR1.2 mg/kg/day 1.2 mg/kg/dayAlterations in vaginal openingReproductive endocrine-mediated perturbations
IVR6 mg/kg/day 6 mg/kg/dayAlterations in vaginal openingReproductive endocrine-mediated perturbations
PMID:11248141IVR0.6 mg/kg/day 0.6 mg/kg/dayDecreased weights of thyroid glandMetabolic endocrine-mediated perturbations
IVR0.6 mg/kg/day 0.6 mg/kg/dayDecreased liver weightsHepatic endocrine-mediated perturbations
IVR6 mg/kg/day 6 mg/kg/dayDecreased weights of thyroid glandMetabolic endocrine-mediated perturbations
PMID:16962624IVTH0.00000001 - 0.0001 M 0.0001 MDecreased testosterone levelsReproductive endocrine-mediated perturbations
IVTH0.00000001 - 0.0001 M 0.0001 MDecreased progesterone levelsReproductive endocrine-mediated perturbations
IVTH0.00000001 - 0.0001 M 0.000001 - 0.0001 MDecreased estradiol levelsReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.